Randomized Phase III SIERRA Trial of 131I-Apamistamab before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML

Boglarka Gyurkocza, Rajneesh Nath, Stuart Seropian, Hannah Choe, Mark R. Litzow, Camille Abboud, Nebu Koshy, Patrick Stiff, Benjamin Tomlinson, Sunil Abhyankar, James Foran, Parameswaran Hari, George Chen, Zaid Al-Kadhimi, Partow Kebriaei, Mitchell Sabloff, Johnnie J. Orozco, Katarzyna Jamieson, Margarida Silverman, Koen Van BesienMichael Schuster, Arjun Datt Law, Karilyn Larkin, Neeta Pandit-Taskar, Scott D. Rowley, Pashna Munshi, Rachel Cook, Moshe Y. Levy, Hillard M. Lazarus, Brenda M. Sandmaier, John M. Pagel, Vijay Reddy, James MacDougall, Kathleen McNamara, Jennifer Spross, Elaina Haeuber, Madhuri Vusirikala, Akash Nahar, Avinash Desai, Sergio Giralt

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'Randomized Phase III SIERRA Trial of 131I-Apamistamab before Allogeneic Hematopoietic Cell Transplantation Versus Conventional Care for Relapsed/Refractory AML'. Together they form a unique fingerprint.

Keyphrases

Medicine and Dentistry

Immunology and Microbiology

Pharmacology, Toxicology and Pharmaceutical Science